No pharmaceutical opinion available for this interaction.
Elvitegravir / Cobicistat can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Glyburide.
Elvitegravir / Cobicistat can induce the metabolism (CYP 2C9) and decrease the plasma concentration of Glyburide.
Elvitegravir 3A4 and then UGT1A1/3; Cobicistat 3A4 (major) and 2D6 (minor)
Elvitegravir : 2C9 (moderate)
Cobicistat : 3A4 and 2D6 (potent), P-gp, MATE 1, BCRP, OATP1B1 and OATP1B3
2C9 and 3A4
Possible increase of the hypoglycemic effect.
Possible decrease of clinical efficacy.
Pharmacodynamic effects difficult to predict.
Monitor the clinical efficacy and appearance of adverse effects.
Adjust dosage if necessary.
Metformin, DPP-4 Inhibitors, GLP-1 Agonists
Signs and symptoms of hypoglycemia : headache, dizziness, tiredness, rapid heartbeat, nervousness, shakiness, nausea and sweating.